TPI [TIANYIN PHARMACEUTICAL] 8-K: (Original Filing)

[FORM 8-K CURRENT REPORT FOR ISSUERS SUBJECT TO THE CURRENT REPORT May 8, 2013 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co., Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]

By | 2016-03-27T18:29:59+00:00 May 9th, 2013|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 10-K/A: (Original Filing)

[FORM 10-K/A (Amendment No. 1) x FOR THE FISCAL YEAR ENDED JUNE 30, 2012 o FOR THE TRANSITION PERIOD FROM TO TIANYIN PHARMACEUTICAL CO., INC. Delaware (State or other jurisdiction of incorporation) (I.R.S. Employer Identification or Organization No.) 23rd Floor, UnionsunYangkuo Plaza No.2, Block 3, Renmin Road South, Chengdu, 610041 P. R. China 0086-028-86154737 and principal place of business) Securities] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this annual report on Form 10-K/A of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James J. Tong, certify that: 1. I have reviewed this annual report on Form 10-K/A of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer, Chief Accounting Officer] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James J. Tong Chief Financial Officer]

By | 2016-03-27T18:38:22+00:00 March 15th, 2013|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 10-K/A: FORM 10-K/A (Amendment No. 1) x FOR THE

[FORM 10-K/A (Amendment No. 1) x FOR THE FISCAL YEAR ENDED JUNE 30, 2012 o FOR THE TRANSITION PERIOD FROM TO TIANYIN PHARMACEUTICAL CO., INC. Delaware (State or other jurisdiction of incorporation) (I.R.S. Employer Identification or Organization No.) 23rd Floor, UnionsunYangkuo Plaza No.2, Block 3, Renmin Road South, Chengdu, 610041 P. R. China 0086-028-86154737 and principal place of business) Securities] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this annual report on Form 10-K/A of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James J. Tong, certify that: 1. I have reviewed this annual report on Form 10-K/A of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer, Chief Accounting Officer] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James J. Tong Chief Financial Officer]

By | 2016-03-27T18:40:03+00:00 March 15th, 2013|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 8-K: (Original Filing)

[TPI Reports Second Quarter Fiscal Year 2013 Financial Results Tianyin Pharmaceutical Inc. CHENGDU, China, February 14, 2013 -- Second Quarter Fiscal Year 2013 Ended December 31, 2012 Financial Highlights: ● Revenue was $17.6 million compared with $18.2 million in 2Q12 a decrease of 3.3% year over year, ● Operating income was $2.6 million, compared with $2.1 million in 2Q12, an] [Tianyin Pharmaceutical Co., Inc. (“TPI”) Second Quarter of Fiscal Year 2013 Earnings Call February 14, 2013 Operator TPI James Tong Second Quarter Fiscal Year 2013 Ended December 31, 2012 Financial Highlights: ● Revenue totaled $17.6 million compared with $18.2 million in 2Q12, a decrease of 3.3% year over year, ● Operating income was $2.6 million, compared with $2.1 million in] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT February 14, 2013 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction (IRS Employer of incorporation) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]

By | 2016-03-27T18:43:28+00:00 February 19th, 2013|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 8-K: TPI Reports Second Quarter Fiscal Year 2013 Financial

[TPI Reports Second Quarter Fiscal Year 2013 Financial Results Tianyin Pharmaceutical Inc. CHENGDU, China, February 14, 2013 -- Second Quarter Fiscal Year 2013 Ended December 31, 2012 Financial Highlights: ● Revenue was $17.6 million compared with $18.2 million in 2Q12 a decrease of 3.3% year over year, ● Operating income was $2.6 million, compared with $2.1 million in 2Q12, an] [Tianyin Pharmaceutical Co., Inc. (“TPI”) Second Quarter of Fiscal Year 2013 Earnings Call February 14, 2013 Operator TPI James Tong Second Quarter Fiscal Year 2013 Ended December 31, 2012 Financial Highlights: ● Revenue totaled $17.6 million compared with $18.2 million in 2Q12, a decrease of 3.3% year over year, ● Operating income was $2.6 million, compared with $2.1 million in] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT February 14, 2013 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction (IRS Employer of incorporation) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]

By | 2016-03-27T18:44:25+00:00 February 19th, 2013|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x For the quarterly period ended December 31, 2012 o For the transition period from _______________ to _______________ Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 +0086-028-86154737 (Address, including zip code, and telephone number,] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended December 31, 2012 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James Jiayuan Tong, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended December 31, 2012 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2)T he information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer, Chief Accounting Officer, Chairman] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James Jiayuan Tong Chief Financial Officer, Director]

By | 2016-03-27T18:46:08+00:00 February 14th, 2013|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments
Skip to toolbar